David Kreimer, Ph.D.
Co-founder and CEO
David Kreimer, Ph.D. is the Chief Executive Officer of Younger Phenotype.
Dr. Kreimer contributed to the foundation of Younger Phenotype by helping crystallize its focus and mission and by inventing critical elements of the company’s technology. With over 35 years of experience in the biotechnology industry and biological sciences, he brings both business leadership skills and sophisticated scientific expertise to Younger Phenotype.
Dr. Kreimer also advanced important understandings of the role of the hypothalamus in relationship to the neuroendocrine mechanisms of aging as a Research Scientist at the Center for Research and Education on Aging (CREA), University of California, Berkeley. Prior to co-founding Younger Phenotype, he co-founded MSM Protein Technologies, Inc., a therapeutic antibody discovery company and served as Chief Operating Officer, and later as President. There he was instrumental in bringing to success a number of collaborative projects, including major collaborations with Cambridge Antibody Technology/AstraZeneca, Merck-Serono, and DebioPharm. He also co-founded and provided leadership for MSM’s subsidiary Meprotek (Pushchino, Moscow area, Russia).
Currently he continues to serve as a member of the MSM Board of Directors. He was Vice President of Research at Tienta Sciences, Inc./ InProteo Consortium (Eli Lilly, and Purdue and Indiana University). David Kreimer served as co-founder, President and Chief Executive Officer of Array BioScience Corporation. Dr. Kreimer consulted for several companies such as Clontech Laboratories, Inc.
He is a co-inventor on a number of patents and patent applications. He performed post-doctoral research at advanced institutions including the Weizmann Institute of Science and University of California, Berkeley. He was awarded a Ph.D. degree in biophysics for his research in protein-lipid interactions at the Institute of Biological Physics (Pushchino), USSR Academy of Sciences.